Compare SYRE & CHE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SYRE | CHE |
|---|---|---|
| Founded | 2013 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 6.8B |
| IPO Year | 2015 | 1994 |
| Metric | SYRE | CHE |
|---|---|---|
| Price | $82.77 | $497.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 5 |
| Target Price | $119.93 | ★ $571.60 |
| AVG Volume (30 Days) | ★ 1.4M | 138.7K |
| Earning Date | 11-03-2026 | 10-27-2026 |
| Dividend Yield | N/A | ★ 0.56% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 9.97 |
| Revenue | N/A | ★ $2,529,978,000.00 |
| Revenue This Year | N/A | $7.56 |
| Revenue Next Year | N/A | $6.05 |
| P/E Ratio | ★ N/A | $50.18 |
| Revenue Growth | N/A | ★ 4.06 |
| 52 Week Low | $21.01 | $365.21 |
| 52 Week High | $110.18 | $557.00 |
| Indicator | SYRE | CHE |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 41.17 |
| Support Level | $82.86 | $496.86 |
| Resistance Level | $94.10 | $518.25 |
| Average True Range (ATR) | 4.63 | 10.57 |
| MACD | -0.13 | -0.19 |
| Stochastic Oscillator | 33.91 | 25.73 |
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.